AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06339294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
Study NCT05771584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-301
Description: 100 μg
Study NCT05771584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF
Description: 100 μg
Study NCT06201208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The ST-Facilitation Psychoeducation Program
Description: One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse.
Study NCT06034678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Allergy Mastery Program
Description: Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
Study NCT05808270 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition care process
Description: According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities.
Study NCT05808270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition care process
Description: According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities.
Study NCT04878302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)
Description: Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
Study NCT05332717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
Study NCT05332717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo (Vitamin C)
Description: Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
Study NCT05080725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TelePEPP intervention
Description: TelePEPP sessions will be conducted twice per week by a Speech Language Pathologist and/or graduate student clinician, on the study team. This clinician will deliver the intervention from the NYU Voice Center using the web conferencing software Webex (institutional license) on a Dell desktop computer with a 3.1 GHz intel core processor and high definition camera. Each exercise set will include 40 repetitions (10 reps of effortful swallows, tongue hold swallows, effortful pitch glides and maximal posterior tongue presses). All exercises are widely-adopted by clinicians as standard of care exercises. The number of sets will be gradually increased as tolerance builds \[2 sets in week 1, 3 sets in week 2, 4 sets in weeks 3+\].
Study NCT05962827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lipoprotein (a)
Description: dosage of lipoprotein (a)
Study NCT06216405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy
Study NCT06216405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy
Study NCT05837546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: presence of a dog, contact between dog and participant
Study NCT05837546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Factice dog intervention
Description: presence of a factice dog, contact between factice dog and participant
Study NCT05837546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant intervention
Description: presence of a plant, contact between plant and participant
Study NCT06537050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JX2105
Description: Oral capsule
Study NCT06537050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT06367777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical a-tsDCS
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
Study NCT06367777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracic a-tsDCS
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
Study NCT06367777 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tsDCS
Description: Sham transcutaneous spinal direct current stimulation (s-tsDCS)
Study NCT04966078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liposuction
Description: suction-assisted liposuction
Study NCT04966078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: periareolar surgical excision
Study NCT04744805 — intervention group
Intervention type: OTHER
Intervention: face mask or not
Description: long term face mask wear
Study NCT05458440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors
Description: The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
Study NCT05330585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
Study NCT05330585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided
Description: Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
Study NCT04895488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks
Study NCT04895488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks
Study NCT04895488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual Antipsychotic Treatment
Description: Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
Study NCT04895488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Antipsychotic Treatment
Description: Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
Study NCT05834023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Lidocaine
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Study NCT05834023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Study NCT04950062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit.
Study NCT04950062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting 16/8 Protocol
Description: Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
Study NCT06544447 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.
Study NCT06544447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.
Study NCT06544447 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study NCT06544447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study NCT06145789 — intervention group
Intervention type: OTHER
Intervention: standing powered wheelchair evaluation
Description: standing powered wheelchair evaluation
Study NCT05743062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
Study NCT05743062 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
Study NCT05158283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chocolate balloon
Description: chocolate balloon dilatation
Study NCT05158283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plain balloon
Description: plain balloon dilatation
Study NCT04813497 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serology to determine SARS-CoV-2 infection
Description: Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
Study NCT05501756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
Study NCT04721899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
Study NCT05721183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOST
Description: The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period.
Study NCT06176469 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05994053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high definition transcranial alternating current stimulation
Description: low intensity alternating current to OFC
Study NCT05994053 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high definition transcranial alternating current stimulation
Description: low intensity alternating current to OFC
Study NCT05872880 — intervention group
Intervention type: PROCEDURE
Intervention: Modified radical surgery
Description: The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.
Study NCT05872880 — intervention group
Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
Study NCT05704179 — intervention group
Intervention type: OTHER
Intervention: Obstetric Quality of recovery score
Description: Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
Study NCT04951713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287 combined with clarithromycin
Description: Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
Study NCT04951713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287 combined with rifampicin
Description: Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
Study NCT06215144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRCT-101SR
Description: NRCT-101SR is a sustained release formulation.
Study NCT06215144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRCT-101SR
Description: NRCT-101SR is a sustained release formulation.
Study NCT05724199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection
Study NCT05724199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study NCT05269589 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water
Description: Participants will immerse their feet in a foot bath that contains thermoneutral water
Study NCT05269589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water
Description: Participants will immerse their feet in a foot bath that contains hot water
Study NCT04542434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: Niclosamide tablets 400 mg 3 times daily for 14 days
Study NCT04542434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets 3 times daily for 14 days